Efficacy and Safety From a High-Dosed Sublingual Grass Pollen Preparation
Information source: Allergopharma Joachim Ganzer KG
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Allergy; Rhinitis; Conjunctivitis
Intervention: Allerslit forte (Biological); Allerslit forte (Biological)
Phase: Phase 3
Status: Recruiting
Sponsored by: Allergopharma Joachim Ganzer KG Official(s) and/or principal investigator(s):
Kristian Reich, Professor, Principal Investigator, Affiliation: not affiliated
Overall contact:
Viola Sprung, Dipl. Dok., Phone: +0049-40-72765-0, Ext: 308, Email: Viola.Sprung@allergopharma.de
Summary
Efficacy and Safety from a high-dosed sublingual grass pollen preparation
Clinical Details
Official title: A Multicentre, Multinational, Placebo-Controlled, Double-Blind, Randomized Study to Evaluate Efficacy and Safety of a Perennial, Sublingual, Specific Immunotherapy in Patients With Rhinoconjunctivitis With/Without Controlled Asthma Caused by Grass Pollen
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Symptom and Medication Score
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Allergic rhinoconjunctivitis attributable to grass pollen
- Positive SPT
- Positive EAST
- Positive provocation Test
Exclusion Criteria:
- Serious chronic disease
- other perennial allergies
Locations and Contacts
Viola Sprung, Dipl. Dok., Phone: +0049-40-72765-0, Ext: 308, Email: Viola.Sprung@allergopharma.de
Prof. Kristian Reich, MD, Hamburg 20354, Germany; Recruiting
Additional Information
Leader in specific allergy research and therapy
Starting date: March 2008
Ending date: February 2012
Last updated: July 14, 2008
|
